When does Xarelto’s patent expire?
The exact patent expiry date for Xarelto depends on the specific patent (or patent family) covering each part of the product, such as the active ingredient, specific dosing regimens, formulations, or manufacturing methods. Patent “expiry” can also differ from regulatory “exclusivity” (drug-data or marketing exclusivity).
Is there a single date or multiple dates?
There usually isn’t one single “Xarelto patent expiry” date because multiple patents can still be active at different times across jurisdictions. That means one generic or biosimilar product launch date may be possible in some countries earlier than in others, depending on which patents have expired and which are still being enforced.
What determines the actual expiry in your country?
Expiry timing varies by:
- The country’s patent term rules (including any adjustments or extensions)
- Whether patent term adjustments were granted
- The existence of additional (secondary) patents filed later
- Whether litigation (or settlement agreements) delays generic entry even after some patents expire
Could generics launch after some patents expire?
Yes. In many cases, generic manufacturers can enter once the patents blocking their specific product are no longer in force or are no longer enforceable. But if other “blocking” patents remain active, entry can be delayed.
What’s the quickest way to find the exact expiry date?
If you share the country (for example, US, UK, EU, Canada, India) and whether you mean “ingredient patent” vs “any Xarelto-related patent,” I can narrow to the relevant expiry/escalation timeline based on the correct jurisdiction.
Sources
No sources were provided in the prompt, so I can’t cite the specific patent expiry date here.